These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 23974194)
21. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610 [TBL] [Abstract][Full Text] [Related]
22. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. McCarthy PL J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979 [TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
25. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912 [TBL] [Abstract][Full Text] [Related]
26. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. Henk HJ; Kaura S J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235 [TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064 [TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers. Saad F; Mulders P Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229 [TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma. Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806 [TBL] [Abstract][Full Text] [Related]
30. Further analyses of the Myeloma IX Study. Morgan GJ Lancet; 2011 Aug; 378(9793):768-9. PubMed ID: 21872746 [No Abstract] [Full Text] [Related]
31. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Witzig TE; Laumann KM; Lacy MQ; Hayman SR; Dispenzieri A; Kumar S; Reeder CB; Roy V; Lust JA; Gertz MA; Greipp PR; Hassoun H; Mandrekar SJ; Rajkumar SV Leukemia; 2013 Jan; 27(1):220-5. PubMed ID: 22902362 [TBL] [Abstract][Full Text] [Related]
32. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852 [TBL] [Abstract][Full Text] [Related]
33. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
35. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349 [TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358 [TBL] [Abstract][Full Text] [Related]
37. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912 [TBL] [Abstract][Full Text] [Related]
38. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis]. Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260 [TBL] [Abstract][Full Text] [Related]
39. [Treatment options and prognosis in newly diagnosed multiple myeloma patients]. Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598 [TBL] [Abstract][Full Text] [Related]
40. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]